Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by Mole101on Aug 17, 2021 10:46pm
196 Views
Post# 33721857

Top House position since June 30..

Top House position since June 30..
 
 
From:  To:  

19,420,802 ($4,072,168) PMN.TO shares exchanged hands from Wed Jun 30 2021 to Tue Aug 17 2021.
House  Bought  Sold  Net 
House 022
Fidelity
Bought $859,553
Volume 4,147,500
Average $0.207
Sold $10,719
Volume 51,073
Average $0.210
Net $848,834
Volume 4,096,427
 
House 068
Leede
Bought $458,857
Volume 2,248,500
Average $0.204
Sold 0
Volume 0
Average 0
Net $458,857
Volume 2,248,500
 
House 080
National Bank
Bought $420,449
Volume 1,918,600
Average $0.219
Sold $204,059
Volume 937,130
Average $0.218
Net $216,390
Volume 981,470
 
House 089
Raymond James
Bought $139,619
Volume 629,836
Average $0.222
Sold $3,122
Volume 15,560
Average $0.201
 
From:  To:  

19,420,802 ($4,072,168) PMN.TO shares exchanged hands from Wed Jun 30 2021 to Tue Aug 17 2021.
House  Bought  Sold  Net 
House 022
Fidelity
Bought $859,553
Volume 4,147,500
Average $0.207
Sold $10,719
Volume 51,073
Average $0.210
Net $848,834
Volume 4,096,427
 
House 068
Leede
Bought $458,857
Volume 2,248,500
Average $0.204
Sold 0
Volume 0
Average 0
Net $458,857
Volume 2,248,500
 
House 080
National Bank
Bought $420,449
Volume 1,918,600
Average $0.219
Sold $204,059
Volume 937,130
Average $0.218
Net $216,390
Volume 981,470
 
House 089
Raymond James
Bought $139,619
Volume 629,836
Average $0.222
Sold $3,122
Volume 15,560
Average $0.201

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities